US FDA approves secnidazole for the treatment of trichomoniasis in adults

Approval is based, in part, on results of a Phase III trial showing a clinically and statistically significant cure rate of 92.2% for patients who had trichomoniasis and no other STIs (94.9% in the per-protocol population); p<0.001 versus placebo (no placebo results presented).

Source:

Biospace Inc.